PTO/SB/26 (12-08) Approved for use through 01/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

## Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional)

## ERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT

Docket Number (Optional) UCSD1530-5

In re Application of: William H. Fenical et al.

Application No.: 10/561,711

Filed: September 11, 2009

For: SALINOSPORAMIDES AND METHODS FOR USE THEREOF

The owner The Regents of the University of California, or 100 percent interest in the instant application where by disclaims, except as provided below, the terminal part of the statutory term of any attent granted on the instant application which would beyond the expiration date of the full statutory term prory patient No. 7,176,233 as the term of said prior patient is defined in 35 U.S.C. 154 and 173, and as the term of said prior patient by presently shortened by any terminal disclaimer. The owner hereby agrees that any patient are commonly owned. This agreement unway that the prior patient are commonly owned. This agreement unway that the prior patient are commonly owned. This agreement unway that the prior patient are commonly owned. This agreement

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the explication date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent sprior pate

expires for failure to pay a maintenance fee;

is held unenforceable;

is found invalid by a court of competent jurisdiction:

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321:

has all claims canceled by a reexamination certificate:

is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements was observed to be true; and further that these statements was on the like so made are purishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may loopardize the validity of the application or any patient issued thereon.

2. The undersigned is an attorney or agent of record. Reg. No. 38,847

Signature

November 28, 2011

Date

Lisa A. Haile, J.D., Ph.D.

Typed or printed name

(858) 677-1456

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 3T CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file goal by the USPTO to proceed an algorithm Confidentially is govered by \$3 U.S. C. 122 and \$7 CFR 1.11 and 1.14. This collection is estimated to bate, including gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of the you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Petation and Trademark Office, U.S. Petation and Trademark Office, U.S. Petation and Trademark Office, U.S. Petation, and Trademark Office, U.S. Petation, and Trademark Office. U.S.